Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
NCT03738319 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2018-11-14
Summary
This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.
Conditions
- High Grade Serous Carcinoma
- Ovarian Cancer
- Exosomes
- Prognosis
- Early Diagnosis
Interventions
- GENETIC
-
Sequencing of miRNA/lncRNA
Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Sponsors & Collaborators
-
Lei Li
lead OTHER
Principal Investigators
-
Lei Li, M.D. · Peking Union Medical College Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-10
- Primary Completion
- 2019-11-23
- Completion
- 2019-11-23
Countries
- China
Study Locations
More Related Trials
-
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
NCT06640348 ·Status: RECRUITING
-
Genetic Mutation in Epithelial Ovarian Cancer
NCT04191252 ·Status: UNKNOWN
-
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
NCT02657928 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
NCT06366997 ·Status: COMPLETED
-
An INternational Frontline Ovarian Cancer Real World Management Study
NCT04460768 ·Status: COMPLETED
-
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
NCT01074398 ·Status: UNKNOWN
-
Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer
NCT05874115 ·Status: UNKNOWN
-
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469 ·Status: COMPLETED
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Research Study in Patients With Advanced Ovarian Epithelial Cancer
NCT00053235 ·Status: WITHDRAWN
-
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06855069 ·Status: RECRUITING ·Phase: PHASE3
-
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
NCT06173037 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06395844 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06884345 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Microtransplantation for Ovarian Cancer
NCT05095558 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
New Biomarkers Evaluating Ovarian Cancer
NCT01466049 ·Status: COMPLETED
-
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
NCT03656809 ·Status: COMPLETED
-
Ribociclib and Letrozole Treatment in Ovarian Cancer
NCT03673124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
NCT06055348 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
NCT05446870 ·Status: COMPLETED ·Phase: PHASE2
-
HRD and Resistance to PAPPi in EOC Patients
NCT05310370 ·Status: UNKNOWN
-
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
NCT06315270 ·Status: NOT_YET_RECRUITING
-
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NCT06420973 ·Status: RECRUITING ·Phase: PHASE2
-
Transcriptional Map of Ovarian Cancer at the Single Cell Level
NCT05030805 ·Status: RECRUITING
-
Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer
NCT06574763 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2